Loading organizations...
Alkermes is a biopharmaceutical company dedicated to developing and commercializing medicines for complex psychiatric and neurological disorders. It applies deep neuroscience expertise and integrated research to create treatments, focusing on addiction, serious mental illness, and sleep disorders. The firm utilizes proprietary technologies to enhance therapeutic efficacy and patient outcomes.
The company was founded in 1987 by Michael Wall. His core insight involved leveraging advanced drug delivery systems to significantly improve treatments for central nervous system disorders. Wall established the firm to apply novel pharmaceutical engineering, addressing critical unmet medical needs via innovative solutions.
Alkermes serves patients contending with chronic psychiatric and neurological conditions, many often stigmatized or lacking adequate therapies. Its long-term vision is to profoundly impact these individuals’ lives by continuously discovering and commercializing innovative medicines. Dedicated to patient-inspired science, it provides meaningful treatment options for overlooked conditions.
Alkermes has 2 tracked investments across 1 company. The latest tracked deal is $55.0M Series C in Civitas Therapeutics in August 2014.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 1, 2014 | Civitas Therapeutics | $55.0M Series C | — | 5AM Ventures, Canaan Partners, Pivotal BioVenture Partners, Sofinnova Investments, SR ONE, Adage Capital Management, BAY City Capital, Canaan Partners, Mark Iwicki, Fountain Healthcare Partners, Longitude Capital, OrbiMed, Partner Fund Management, RA Capital Management, Rock Springs Capital, Wellington Management |
| Sep 1, 2013 | Civitas Therapeutics | $38.0M Series B | ROB Hopfner | 5AM Ventures, Canaan Partners, Pivotal BioVenture Partners, Sofinnova Investments, SR ONE, Canaan Partners, Fountain Healthcare Partners, Longitude Capital, Rajeev Shah |
